Changes in aqueous and vitreous inflammatory cytokine levels in diabetic macular oedema: a systematic review and meta‐analysis. Issue 1 (4th May 2021)

• Record Type: Journal Article
• Authors: Minaker, Samuel A.; Mason, Ryan H.; Lahaie Luna, Gabriela; Farahvash, Armin; Garg, Anubhav; Bhambra, Nishaant; Bapat, Priya; Muni, Rajeev H.
• Is Part Of: Acta ophthalmologica. Volume 100:Issue 1(2022)
• Page Start: e53
• Page End: e70
• Publication Date: 2021-05-04
• Subjects: cytokines -- diabetic macular oedema -- meta‐analysis -- ocular biomarkers; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1111/aos.14891
• Languages: English
• ISSNs: 1755-375X

Abstract

Abstract: Diabetic macular oedema (DME) is considered a chronic inflammatory disease associated with aberrations in many intraocular cytokines. Studies assessing the role of these cytokines as biomarkers in the diagnosis and management of DME have demonstrated inconsistent findings. We quantitatively summarized data related to 116 candidate aqueous and vitreous inflammatory cytokines as biomarkers in DME. A systematic search without year limitation was performed up to 19 October 2020. Studies were included if they provided data on aqueous or vitreous cytokine concentrations in patients with DME. Effect sizes were generated as standardized mean differences (SMDs) of cytokine concentrations between patients with DME and controls. Data were extracted from 128 studies that included 4163 study eyes with DME and 1281 control eyes. Concentrations (standard mean difference, 95% confidence interval and p‐value) of aqueous IL‐6 (1.28, 0.57–2.00, p = 0.004), IL‐8 (1.06, 0.74–1.39, p < 0.00001), MCP‐1 (1.36, 0.57–2.16, p = 0.0008) and VEGF (1.31, 1.01–1.62, p < 0.00001) and vitreous VEGF (2.27, 1.55–2.99, p < 0.00001) were significantly higher in patients with DME ( n = 4163) compared to healthy controls ( n = 1281). No differences, failed sensitivity analyses or insufficient data were found between patients with DME and healthy controls for the concentrations of the remaining cytokines. This analysis implicates multiple cytokine biomarker candidates other than VEGF in DME and clarifies previously reported inconsistent associations. As the therapeutic options for DME expand to include multiple agents with multiple targets, it will be critical to manage the treatment burden with tailored therapy that optimizes outcomes and minimizes treatment burden. Intraocular cytokines have the promise of providing a robust individualized assessment of disease status and response to therapy. We have identified key candidate cytokines that may serve as biomarkers in individualized treatment algorithms.